Translational Research in Oncology — Innovations in Model Development, Upcoming Webinar Hosted by Xtalks
In this educational webinar, learn about the latest innovations in preclinical cancer modeling. This talk will cover advancements in patient-derived xenograft (PDX) development, models of spontaneous metastases and other sophisticated approaches to modeling relevant clinical scenarios. Attendees will learn how whole-body and focal radiation can be used to mimic clinical scenarios in both in vivo and in vitro studies. The featured speakers will discuss the importance of choosing the right type of model to support each study’s purpose and reducing variability between in vitro and in vivo studies by employing matched pairs of patient-derived xenograft (PDX) models and three-dimensional cell cultures derived from them. Attendees will learn about emerging approaches to humanized PDX models to recapitulate the human tumor microenvironment and evaluate immune response.
To develop the next generation of targeted cancer therapies, researchers need cancer models that can stand in as true proxies for human disease. Traditional research models commonly used in commercial applications have a place in screening and can provide directional information about potential therapeutic responses. However, they do not replicate the heterogenous biology and complex network of dysregulated pathways that characterize real-life human tumors. In fact, most models used in preclinical drug development fail to address the importance of tumor microenvironment, despite its well-established role in druggability and immune response. Translational research in oncology can greatly benefit from improvements to these models.
Innovative approaches to model development can address many shortcomings of legacy models. What’s more, both in vitro and in vivo test systems can now be customized to account for the myriad of clinical scenarios (prior treatment, radiotherapy, acquired resistance, metastases) that may ultimately determine clinical response to a given experimental therapy.
Translational research success is largely dependent upon selecting — or sometimes custom-developing — the most appropriate preclinical model to assess a candidate’s therapeutic response. During this webinar, the featured speakers will review current literature on cell culture, organoids/spheroids and various types of in vivo mouse models and discuss emerging techniques for developing more clinically relevant models of cancer.
Register to learn about the innovations in preclinical model development for translational research in oncology.
Join experts from Certis Oncology Solutions, Jonathan Nakashima, PhD, Chief Scientific Officer; Jantzen Sperry, PhD, Senior Director, Scientific Operations; and Rajeev Shrimali, PhD, Senior Director, Immuno-Oncology R&D, for the live webinar on Wednesday, December 14, 2022, at 2pm EST (11am PST).
For more information, or to register for this event, visit Translational Research in Oncology — Innovations in Model Development.
About Certis Oncology Solutions
Certis Oncology Solutions is a life science technology company specializing in custom cancer model development, from advanced cellular and in vivo models of recurrence, resistance and metastasis, to rare and humanized mouse models. We are committed to realizing the promise of precision oncology. Our product is Oncology Intelligence™ — highly predictive therapeutic response data derived from advanced biological models of cancer. Our proprietary platform informs individual treatment decisions and accelerates the development of new cancer therapies.
MEDIA CONTACT
Certis Oncology Solutions
Kristein King
kking@certisoncology.com
573-818-4528